Loading...
Loading...
Insmed INSM shareholders are having a big day. Shares are up 31.2 percent after the company announced that the FDA granted Arikayce breakthrough therapy designation.
Arikayce is designed to treat lung infections; more specifically nontuberculous mycobacterial lung disease.
Insmed further stated that the designation was based on results from the phase two trial and the company plans to meet with the FDA to form a regulation pathway.
Shares were last trading at $16.34, a 31.2 percent gain.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in